Gefitinib: A new agent in palliative care

Eric Prommer

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

In 2003, gefitinib (Iressa®, AstraZaneca, London, UK) in 250 mg tablet form received accelerated approval by the US Food and Drug Administration. Gefitinib targets the cancer cell at the molecular level and has the ability to palliate lung cancer symptoms. Gefitinib's ability to control symptoms with minimal toxicity provides physicians with a new option to complement current symptom control methods. It is nonmarrow suppressive and seems to have an ability to control symptoms quickly, even in the absence of obvious tumor reduction. However, further studies are needed to compare gefitinib's ability to control symptoms with intensive palliative modalities for lung cancer, such as opioids, oxygen, and radiation therapy.

Original languageEnglish (US)
Pages (from-to)222-227
Number of pages6
JournalAmerican Journal of Hospice and Palliative Medicine
Volume21
Issue number3
StatePublished - May 2004
Externally publishedYes

Fingerprint

Palliative Care
Lung Neoplasms
United States Food and Drug Administration
Opioid Analgesics
Tablets
Neoplasms
Radiotherapy
gefitinib
Oxygen
Physicians

Keywords

  • Cancer pain
  • Gefitinib
  • Pharmacotherapy
  • Symptom management

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gefitinib : A new agent in palliative care. / Prommer, Eric.

In: American Journal of Hospice and Palliative Medicine, Vol. 21, No. 3, 05.2004, p. 222-227.

Research output: Contribution to journalArticle

@article{845524f0f38645ef8d726df93d58a815,
title = "Gefitinib: A new agent in palliative care",
abstract = "In 2003, gefitinib (Iressa{\circledR}, AstraZaneca, London, UK) in 250 mg tablet form received accelerated approval by the US Food and Drug Administration. Gefitinib targets the cancer cell at the molecular level and has the ability to palliate lung cancer symptoms. Gefitinib's ability to control symptoms with minimal toxicity provides physicians with a new option to complement current symptom control methods. It is nonmarrow suppressive and seems to have an ability to control symptoms quickly, even in the absence of obvious tumor reduction. However, further studies are needed to compare gefitinib's ability to control symptoms with intensive palliative modalities for lung cancer, such as opioids, oxygen, and radiation therapy.",
keywords = "Cancer pain, Gefitinib, Pharmacotherapy, Symptom management",
author = "Eric Prommer",
year = "2004",
month = "5",
language = "English (US)",
volume = "21",
pages = "222--227",
journal = "American Journal of Hospice and Palliative Medicine",
issn = "1049-9091",
publisher = "SAGE Publications Inc.",
number = "3",

}

TY - JOUR

T1 - Gefitinib

T2 - A new agent in palliative care

AU - Prommer, Eric

PY - 2004/5

Y1 - 2004/5

N2 - In 2003, gefitinib (Iressa®, AstraZaneca, London, UK) in 250 mg tablet form received accelerated approval by the US Food and Drug Administration. Gefitinib targets the cancer cell at the molecular level and has the ability to palliate lung cancer symptoms. Gefitinib's ability to control symptoms with minimal toxicity provides physicians with a new option to complement current symptom control methods. It is nonmarrow suppressive and seems to have an ability to control symptoms quickly, even in the absence of obvious tumor reduction. However, further studies are needed to compare gefitinib's ability to control symptoms with intensive palliative modalities for lung cancer, such as opioids, oxygen, and radiation therapy.

AB - In 2003, gefitinib (Iressa®, AstraZaneca, London, UK) in 250 mg tablet form received accelerated approval by the US Food and Drug Administration. Gefitinib targets the cancer cell at the molecular level and has the ability to palliate lung cancer symptoms. Gefitinib's ability to control symptoms with minimal toxicity provides physicians with a new option to complement current symptom control methods. It is nonmarrow suppressive and seems to have an ability to control symptoms quickly, even in the absence of obvious tumor reduction. However, further studies are needed to compare gefitinib's ability to control symptoms with intensive palliative modalities for lung cancer, such as opioids, oxygen, and radiation therapy.

KW - Cancer pain

KW - Gefitinib

KW - Pharmacotherapy

KW - Symptom management

UR - http://www.scopus.com/inward/record.url?scp=2642551296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2642551296&partnerID=8YFLogxK

M3 - Article

C2 - 15188923

AN - SCOPUS:2642551296

VL - 21

SP - 222

EP - 227

JO - American Journal of Hospice and Palliative Medicine

JF - American Journal of Hospice and Palliative Medicine

SN - 1049-9091

IS - 3

ER -